| 1 |
Storandt MH, Jin Z, Mahipal A. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion. Expert Rev Anticancer Ther 2022;22:1265-74. [PMID: 36408971 DOI: 10.1080/14737140.2022.2150168] [Reference Citation Analysis]
|
| 2 |
Dong Y, Ren C, Zhu M, Zhang D, Wang T, Zhang J, Wang J, Mao W, Long F. Targeting FGFRs for tumor therapy: current status and novel strategies. Future Med Chem 2022;14:1923-41. [PMID: 36449352 DOI: 10.4155/fmc-2022-0194] [Reference Citation Analysis]
|
| 3 |
Rizzo A, Salati M, Frega G, Merz V, Caputo F, Di Federico A, Palloni A, Carloni R, Ricci AD, Gadaleta-Caldarola G, Messina C, Spallanzani A, Gelsomino F, Benatti S, Luppi G, Melisi D, Dominici M, Brandi G. Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study. Medicina (Kaunas) 2022;58. [PMID: 36363500 DOI: 10.3390/medicina58111543] [Reference Citation Analysis]
|
| 4 |
Lu Y, Li X, Zhao K, Shi Y, Deng Z, Yao W, Wang J. Proteomic and Phosphoproteomic Profiling Reveals the Oncogenic Role of Protein Kinase D Family Kinases in Cholangiocarcinoma. Cells 2022;11:3088. [PMID: 36231050 DOI: 10.3390/cells11193088] [Reference Citation Analysis]
|
| 5 |
Brandi G, Rizzo A. IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience? Int J Mol Sci 2022;23:10869. [PMID: 36142781 DOI: 10.3390/ijms231810869] [Reference Citation Analysis]
|
| 6 |
Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, Cristoferi L, Ciaccio A, Cortinovis DL, Invernizzi P, Massironi S. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol 2022;27:100737. [PMID: 35809836 DOI: 10.1016/j.aohep.2022.100737] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 7 |
Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021. Naunyn Schmiedebergs Arch Pharmacol 2022. [PMID: 35543739 DOI: 10.1007/s00210-022-02250-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 8 |
Zheng J, Zhang W, Li L, He Y, Wei Y, Dang Y, Nie S, Guo Z. Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review. Front Chem 2022;10:860985. [DOI: 10.3389/fchem.2022.860985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacol Res 2021;175:106037. [PMID: 34921994 DOI: 10.1016/j.phrs.2021.106037] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 18.5] [Reference Citation Analysis]
|
